Canada
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Genevant Sciences.
EMERYVILLE, CALIFORNIA, VANCOUVER, BRITISH COLUMBIA, and BASEL, SWITZERLAND — August 15, 2023 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced an agreement pursuant to which Gritstone bio, Inc. will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.
This is the News section of the company profile page for Genevant Sciences on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
